On the other hand, similar to the non-redundant role of PTPROt in BCR signaling in CLL, downregulation of PTPROt due to frequent methylation has been demonstrated to relate with aggravated diseases evidenced by clinical samples as well as in vivo and in vitro experiments, which can be attenuated by DNA hypomethylating drug decitabine (5-aza-deoxycytidine) to restore PTPROt expression (41, 57). Here, BCR is linked to B-cell chronic lymphocytic leukemia.